12 June 2026
The Brazilian Ministry of Health has announced a temporary suspension of its mass immunization campaign using the domestically produced Butantan-DV vaccine, pending an investigation into the deaths of two vaccine recipients.
Brazilian health authorities have ordered a precautionary halt to the rollout of Butantan-DV, a newly developed single-dose dengue vaccine produced by the country's renowned Instituto Butantan in partnership with WuXi Vaccines. The decision follows reports of two suspected fatalities, a 58-year-old man and a 48-year-old woman, as well as a third recipient who required emergency admission to an intensive care unit. These severe adverse events occurred among approximately 500,000 individuals who have received the vaccine since its recent introduction.
Approved Dengue Vaccines
- Qdenga (Takeda): A live-attenuated vaccine designed to provide protection against all four dengue virus serotypes. Qdenga is administered as a two-dose regimen, with doses given three months apart.
- Dengvaxia (Sanofi Pasteur): The first dengue vaccine to receive regulatory approval. However, its use is now highly restricted. It is indicated exclusively for individuals aged 9 to 45 years with laboratory-confirmed evidence of a previous dengue infection.
The current concern in Brazil inevitably recalls one of the most controversial public health crises of the 21st century. In 2015, the French pharmaceutical company Sanofi Pasteur launched Dengvaxia to widespread acclaim. In collaboration with the Philippine government, the company initiated a large-scale school-based immunization program that ultimately vaccinated more than 800,000 children.
However, in 2017, the manufacturer disclosed a critical scientific finding: while the vaccine provided substantial protection to individuals who had previously experienced a natural dengue infection, it posed a significant risk to dengue-naïve (seronegative) individuals who had never been infected with the virus. In these children, the vaccine effectively simulated a primary infection. When they were subsequently exposed to wild-type dengue virus, their immune systems could respond through a phenomenon known as Antibody-Dependent Enhancement (ADE), increasing the risk of severe and potentially life-threatening disease.
The resulting fallout in the Philippines triggered unprecedented political, legal, and criminal investigations involving public health officials, led to the revocation of the vaccine's local registration, and contributed to a profound and long-lasting decline in public confidence in vaccination programs throughout the region.